

## Hyperbaric oxygen pretreatment and preconditioning

Enrico M. Camporesi, M.D.<sup>1</sup>, Gerardo Bosco, M.D., Ph.D.<sup>2</sup>

<sup>1</sup> Emeritus Professor of Surgery /Anesthesiology and Molecular Pharmacology/Physiology, University of South Florida, Tampa, Florida USA

<sup>2</sup> Assistant Professor, Department of Biomedical Sciences, University of Padova and ATIP Hyperbaric Medical Center, Padova, Italy

CORRESPONDING AUTHOR: Dr. Enrico Camporesi – [ecampore@health.usf.edu](mailto:ecampore@health.usf.edu)

---

### ABSTRACT

Exposure to hyperbaric oxygen (HBO<sub>2</sub>) before a crucial event, with the plan to create a preventing therapeutic situation, has been defined “preconditioning” and is emerging as a useful adjunct both in diving medicine as well before ischemic or inflammatory events. Oxygen pre-breathing before diving has been extensively documented in recreational, technical, commercial and military diving for tissue denitrogenation, resulting in reduced post-diving bubble loads, reduced decompression requirements and more rapid return to normal platelet function after a decompression. Preoxygenation at high atmospheric pressure has also been used in patients before exposure to clinical situations with beneficial effects, but the mechanisms of action have not yet

been ascertained. During the reperfusion of ischemic tissue, oxygenated blood increases numbers and activities of oxidants generated in tissues. Previous reports showed that HBO<sub>2</sub> preconditioning caused the activation of antioxidative enzymes and related genes in the central nervous system, including catalase (CAT), superoxide dismutase and heme oxygenase-1. Despite the increasing number of basic science publications on this issue, studies describing HBO<sub>2</sub> preconditioning in the clinical practice remain scarce. To date, only a few studies have investigated the preconditioning effects of HBO<sub>2</sub> in relation to the human brain and myocardium with robust and promising results.

---

### RATIONALE

Preoxygenation by breathing elevated concentrations of oxygen (O<sub>2</sub>) before an event has been documented to induce various effects that mirror the physiologic and therapeutic applications demonstrated both in extreme environments and in selected clinical applications. In the most trivial form, 100% oxygen prebreathing has been used to extend useful apnea time during breath-hold diving and to denitrogenate the lungs and other tissues before flights at very high altitudes or even before extravehicular activities (EVA) in space at reduced ambient pressure. A clinical counterpart is a recommended safety maneuver to extend safe intubation time after rapid induction of anesthesia and muscle paralysis, allowing prolonged laryngoscopy exposure time for tracheal intubation, especially in patients at risk of rapid desaturation following apnea such as pregnant women, small children and the obese.

### Diving medicine applications

It has been exhaustively documented that oxygen exposure can be successfully utilized for recreational, technical, commercial [1] and military diving [2]. Among the clinical conditions that can be treated with oxygen therapy, decompression sickness (DCS) is one of the most common complications [3].

HBO<sub>2</sub> and normobaric oxygen (NBO<sub>2</sub>) prebreathing maneuvers have been shown to be beneficial in preventing or reducing air bubble formation and platelet activation after a given dive profile, thus reducing the development of DCS [4,5]. Bosco and colleagues demonstrated that in-water O<sub>2</sub> prebreathing at a depth of 6 or 12 msw led to lower bubble scores than prebreathing O<sub>2</sub> at the surface in open-water sea divers after a set dive exposure [5]. The HBO<sub>2</sub> preconditioning procedure for denucleation may have a potential application in decreasing the DCS risk in humans. In addition, the authors showed that pre-

breathing HBO<sub>2</sub> constitutes an overall more efficient treatment than NBO<sub>2</sub> for reducing decompression-induced bubble formation and platelet activation [5].

The in-water prebreathing treatment has also been tested at higher depth (30 msw) for short exposure times, and the oxidative status and intracellular calcium ([Ca<sup>2+</sup>]<sub>i</sub>) of peripheral blood lymphocytes have been analyzed [6]. Results from this work showed additionally that prebreathing oxygen may enhance lymphocyte antioxidant activity and reduce ROS levels. Prebreathing oxygen in water may also preserve calcium homeostasis, suggesting a protective role in the physiological lymphocyte cell functions. Notably, the authors found augmented catalase enzyme activity as well as increases in catalase, superoxide dismutase and glutathione peroxidase mRNA gene expression, which were interpreted as an enhanced antioxidant defense. In addition, no [Ca<sup>2+</sup>]<sub>i</sub> increase was observed, thus suggesting supplementary evidence of a decreased oxidative stress [6].

In 2006, Landolfi and colleagues demonstrated that the partial pressure of dissolved nitrogen in fast tissues at 4 atmospheres absolute (atm abs) (405.30 kPa) after compression was similar between the groups of tissues that received previous hyperbaric oxygen and those that did not receive preoxygenation, thus suggesting that the N<sub>2</sub> washout effect by oxygen at ground level is quickly neutralized at depth [7]. The authors also reported a reduction of post-decompression bubble formation from 4 atm abs (405.30 kPa) after pretreatment with oxygen at 1.6 atm abs (162.12 kPa). This finding is consistent with the mechanism of gas nuclei elimination by oxygen pretreatment [8]. Indeed, previous experimental studies have shown that the delay for regeneration of a depleted gas nuclei population may be of the order of a few hours up to 100 hours [9].

In the same vein, an elegant 2009 study from Castagna and collaborators showed that breathing NBO<sub>2</sub> for 30 minutes before an open water air dive provided significant reduction in decompression-induced bubble formation, observed after the evaluation of venous gas emboli (VGE), Doppler ultrasound and bubble formation score [2]. VGE production is higher for repetitive dives than for a single dive [10], with a more significant risk of developing DCS following multiday repetitive dives [11]. Castagna [2] addresses three different hypotheses to explain how reduction of VGE can be dependent upon oxygen prebreathing: Denitrogenation,

gas nuclei removal and hemodynamic effects. Notably in denitrogenation, inert gases accumulated in tissues diffuse more easily toward the bloodstream after a hyperoxic exposure that causes arterial O<sub>2</sub> pressure increase. This process reduces tissue N<sub>2</sub> supersaturation, thus preventing bubble production [12]. In addition, it has been reported that further protection against the onset of DCS is provided by exercise because increased metabolic levels improve ventilation, perfusion and diffusion during preoxygenation before altitude decompression [13]. In gas nuclei removal, O<sub>2</sub> has the potential of replacing N<sub>2</sub> in the nucleus by diffusion, thus eliminating pre-existing gas micronuclei prior to the bubble formation process [7,14,15]. Moreover, it has been shown that O<sub>2</sub> is responsible for the removal of protein-coated bubbles by the lymphatic bed [16], suggesting a reduction of gas nuclei in both venous and lymphatic systems [2]. However, it was demonstrated that this preoxygenation procedure causes a reduction in bubble size but not density [8]. Regarding hemodynamic effects, a significant heart rate and cardiac output decrease in parallel with a vascular resistance increase were found to follow a hyperoxic preconditioning at sea level for one hour in healthy subjects [17]. These adaptations persisted for more than an hour after restoring the environmental 21% O<sub>2</sub> [18].

### Hyperbaric medicine applications

Preoxygenation at high atmospheric pressure has been used in patients before exposure to clinical situations with beneficial effects, but the mechanisms of action have not yet been ascertained. During the reperfusion of ischemic tissue, oxygenated blood increases numbers and activities of oxidants generated in tissues. Reperfusion increases the hazardous effects of early ischemic injury by release of cytokines and reactive oxygen species such as hydroxyl radical (•OH), superoxide radical (O<sub>2</sub><sup>-</sup>), and hydrogen peroxide (H<sub>2</sub>O<sub>2</sub>) and by the activation of a complement system. This phenomenon has been broadly named ischemia-reperfusion (I/R) injury. All tissues can be involved in I/R, and animal models demonstrating the tolerance and vulnerability of different organs have been presented. There are many studies investigating I/R injury in different tissues such as kidney, liver, lung, testis, brain, heart muscle and skeletal muscle in the literature [19]. I/R injury in skeletal muscles and in bone may occur with vascular problems, including atherosclerotic occlusive disease, arterial thrombosis, or arterial

embolism, and after organ transplantation, cardiovascular surgery and vascular trauma [20]. In addition, limb ischemia-reperfusion occurs often in surgical procedures, such as when using a tourniquet to provide a bloodless surgical field [21].

In fact, despite improvements in surgical techniques and in anesthetic management, I/R injury remains an inevitable event of cardiac surgery, resulting in significant postoperative complications and multiple-organ dysfunction. Ischemia-reperfusion injury during cardiopulmonary bypass (CPB) also leads to myocardial stunning, necrosis or apoptosis that manifests clinically either acutely as low cardiac output or chronically as heart failure [22]. To date, brain injury after CPB for cardiac surgery has been well documented. Sequelae can be as mild as postoperative cognitive dysfunction and postoperative delirium and as severe as stroke [23]. The etiology of cerebral injuries is probably multifactorial, from an interaction among cerebral microemboli, global cerebral hypoperfusion, inflammation, cerebral temperature modulation and genetic susceptibility [24].

Preconditioning is defined as the application of an intervention to activate endogenous protective mechanisms to potentially lessen the morphologic and functional sequelae of a subsequent ischemia insult. The phenomenon of ischemic preconditioning was first described in a canine myocardium ischemia-reperfusion injury model [25] and subsequently was shown in the brain [26]. Since then, intense research in the field of pharmacology has progressed to identify agents such as volatile anesthetic agents and ischemic preconditioning [27-29] that could duplicate the protective effects of preconditioning for cardiac surgery.

Previous reports showed that HBO<sub>2</sub> preconditioning caused the activation of antioxidative enzymes and related genes in the central nervous system including catalase (CAT), superoxide dismutase and heme oxygenase-1 [30-32]. Despite the increasing number of basic science publications on this issue, studies describing HBO<sub>2</sub> preconditioning in the clinical practice of cardiac surgery remain scarce. To date, only a few studies have investigated the preconditioning effects of HBO<sub>2</sub> in relation to the human brain and myocardium.

In 2004, Sharifi, *et al.* [33] described the successful use of HBO<sub>2</sub> to inhibit restenosis after percutaneous transluminal coronary intervention (PTCI) in acute myocardial infarction. In 2005, Alex, *et al.* [34] ob-

served that repetitive pretreatment with three sessions of HBO<sub>2</sub> at 2.4 atm abs (243.18 kPa) before on-pump coronary artery bypass graft (CABG) surgery reduced neuropsychometric dysfunction and modulated favorably the inflammatory response after CPB. More recently, Yogaratnam, *et al.* [35] reported that preconditioning with a single session of HBO<sub>2</sub> at 2.5 atm abs (253.32 kPa) for 90 minutes before on-pump CABG surgery improved left ventricular stroke work post-CABG surgery while reducing intraoperative blood loss, ICU length of stay, and postoperative complications.

Additionally, Li, *et al.* [36] aimed to determine whether HBO<sub>2</sub> preconditioning could decrease the release of cerebral and myocardial biochemical markers such as S100B protein, neuron-specific enolase (NSE), and troponin I (cTnI) in the peri- and post-CABG surgery period. The primary end point of this last extensive study was to show that repeated HBO<sub>2</sub> preconditioning sessions significantly decreased release of S100B and NSE. A secondary end point of this study was to assess the effects of HBO<sub>2</sub> preconditioning on serum troponin I, inotrope usage, ventilator hours, length of ICU stay, postoperative duration of hospital stay, hemodynamic parameters and serum CAT activity. This study demonstrated positive results on the cardiac and neurologic functions of repeated HBO<sub>2</sub> preconditioning in on-pump surgery patients, but not for off-pump CABG surgery patients. The authors interpret these data as an indication that more ischemic events were happening during cardiopulmonary bypass and were prevented by preoxygenation.

A recent experimental paper has identified an important mechanism involved in triggering the beneficial effect of HBO<sub>2</sub> preconditioning, as the intracellular induction of heme-oxygenase-1 in hepatic IR injury [37]. Whether the various preconditioning protocol factors such as pressure, frequency or lag time before surgery contributes to the different results should be investigated in further studies and applied to diverse surgical procedures, especially major surgeries leading to postoperative ICU admission.

#### **Conflict of interest**

*The authors have declared that no conflict of interest exists with this submission.*

## REFERENCES

1. Piepho T, Ehrmann U, Werner C, Muth CM. Oxygen therapy in diving accidents. *Anaesthesist*. 2007;56:44-52.
2. Castagna O, Gempp E, Blatteau JE. Pre-dive normobaric oxygen reduces bubble formation in scuba divers. *Eur J Appl Physiol*. 2009;106:167-172.
3. Vann RD, Denoble PJ, Howle LE, Weber PW, Freiburger JJ, Pieper CF. Resolution and severity in decompression illness. *Aviat Space Environ Med*. 2009;80:466-471.
4. Arieli R, Boaron E, Arieli Y, Abramovich A, Katsenelson K. Oxygen pretreatment as protection against decompression sickness in rats: pressure and time necessary for hypothesized denucleation and renucleation. *Eur J Appl Physiol*. 2011;111:997-1005.
5. Bosco G, Yang ZJ, Di Tano G, Camporesi EM, Faralli F, Savini F, Landolfi A, Doria C, Fano G. Effect of in-water oxygen prebreathing at different depths on decompression-induced bubble formation and platelet activation. *J Appl Physiol*. 2010;108:1077-1083.
6. Morabito C, Bosco G, Pilla R, Corona C, Mancinelli R, Yang Z, Camporesi EM, Fano G, Mariggio MA. Effect of pre-breathing oxygen at different depth on oxidative status and calcium concentration in lymphocytes of scuba divers. *Acta Physiol (Oxf)*. 2011;202:69-78.
7. Landolfi A, Yang Z, Savini F, Camporesi E, Faralli F, Bosco G. Pre-treatment with hyperbaric oxygenation reduces bubble formation and platelet activation. *Sport Sciences for Health*. 2006;1:122-128.
8. Arieli Y, Arieli R, Marx A. Hyperbaric oxygen may reduce gas bubbles in decompressed prawns by eliminating gas nuclei. *J Appl Physiol*. 2002;92:2596-2599.
9. Younth DE. On the evolution, generation, and regeneration of gas cavitation nuclei. *J Acoust Soc Am*. 1982;71:1473-1481.
10. Dunford RG, Vann RD, Gerth WA, Pieper CF, Huggins K, Wacholtz C, Bennett PB. The incidence of venous gas emboli in recreational diving. *Undersea Hyperb Med*. 2002;29:247-259.
11. Hamilton RW, Thalmann ED. Decompression practice. In: Brubakk AO, Neuman TS, editors. *Bennett & Elliott's Physiology and Medicine of Diving*. 5th ed. New York, NY: Elsevier Science; 2003. P. 455-500.
12. Behnke AR. The isobaric (oxygen window) principle of decompression. In: *The new thrust seaward*. Transactions of the third annual conference of marine technology society. San Diego, CA: Marine Technology Society; 1967.
13. Webb JT, Pilmanis AA. Preoxygenation time versus decompression sickness incidence. *SAFE J*. 1999;29:75-78.
14. Butler BD, Little T, Cogan V, Powell M. Hyperbaric oxygen pre-breathe modifies the outcome of decompression sickness. *Undersea Hyperb Med*. 2006;33:407-417.
15. Katsenelson K, Arieli Y, Abramovich A, Feinsod M, Arieli R. Hyperbaric oxygen pretreatment reduces the incidence of decompression sickness in rats. *Eur J Appl Physiol*. 2007;101:571-576.
16. Balestra C, Germonpre P, Snoeck T, Ezquer M, Leduc O, Leduc A, Willeput F, Marroni A, Cali Corleo R, Vann R. Normobaric oxygen can enhance protein captation by the lymphatic system in healthy humans. *Undersea Hyperb Med*. 2004;31:59-62.
17. Waring WS, Thomson AJ, Adwani SH, Rosseel AJ, Potter JF, Webb DJ, Maxwell SR. Cardiovascular effects of acute oxygen administration in healthy adults. *J Cardiovasc Pharmacol*. 2003;42:245-250.
18. Thomson AJ, Drummond GB, Waring WS, Webb DJ, Maxwell SR. Effects of short-term isocapnic hyperoxia and hypoxia on cardiovascular function. *J Appl Physiol*. 2006;101:809-816.
19. Yu SY, Chiu JH, Yang SD, Yu HY, Hsieh CC, Chen PJ, Lui WY, Wu CW. Preconditioned hyperbaric oxygenation protects the liver against ischemia-reperfusion injury in rats. *J Surg Res*. 2005;128:28-36.
20. Grisotto PC, dos Santos AC, Coutinho-Netto J, Cherri J, Piccinato CE. Indicators of oxidative injury and alterations of the cell membrane in the skeletal muscle of rats submitted to ischemia and reperfusion. *J Surg Res*. 2000;92:1-6.
21. Ozyurt H, Ozyurt B, Koca K, Ozgocmen S. Caffeic acid phenethyl ester (CAPE) protects rat skeletal muscle against ischemia-reperfusion-induced oxidative stress. *Vascul Pharmacol*. 2007;47:108-112.
22. Bolli R, Becker L, Gross G, Mentzer R Jr., Balshaw D, Lathrop DA. Myocardial protection at a crossroads: the need for translation into clinical therapy. *Circ Res*. 2004;95:125-134.
23. Gao L, Taha R, Gauvin D, Othmen LB, Wang Y, Blaise G. Postoperative cognitive dysfunction after cardiac surgery. *Chest*. 2005;128: 3664-3670.
24. Sato Y, Laskowitz DT, Bennett ER, Newman MF, Warner DS, Grocott HP. Differential cerebral gene expression during cardiopulmonary bypass in the rat: evidence for apoptosis? *Anesth Analg*. 2002;94:1389-1394, table of contents.
25. Murry CE, Jennings RB, Reimer KA. Preconditioning with ischemia: a delay of lethal cell injury in ischemic myocardium. *Circulation*. 1986;74:1124-1136.

26. Kitagawa K, Matsumoto M, Tagaya M, Hata R, Ueda H, Niinobe M, Handa N, Fukunaga R, Kimura K, Mikoshiba K, et al. 'Ischemic tolerance' phenomenon found in the brain. *Brain Res.* 1990;528:21-24.
27. Hausenloy DJ, Mwamure PK, Venugopal V, Harris J, Barnard M, Grundy E, Ashley E, Vichare S, Di Salvo C, Kolvekar S, Hayward M, Keogh B, MacAllister RJ, Yellon DM. Effect of remote ischaemic preconditioning on myocardial injury in patients undergoing coronary artery bypass graft surgery: a randomised controlled trial. *Lancet.* 2007;370:575-579.
28. Wu ZK, Iivainen T, Pehkonen E, Laurikka J, Tarkka MR. Arrhythmias in off-pump coronary artery bypass grafting and the antiarrhythmic effect of regional ischemic preconditioning. *J Cardiothorac Vasc Anesth.* 2003;17:459-464.
29. Yellon DM, Alkhulaifi AM, Pugsley WB. Preconditioning the human myocardium. *Lancet.* 1993;342:276-277.
30. Li Q, Li J, Zhang L, Wang B, Xiong L. Preconditioning with hyperbaric oxygen induces tolerance against oxidative injury via increased expression of heme oxygenase-1 in primary cultured spinal cord neurons. *Life Sci.* 2007;80:1087-1093.
31. Sterling DL, Thornton JD, Swafford A, Gottlieb SF, Bishop SP, Stanley AW, Downey JM. Hyperbaric oxygen limits infarct size in ischemic rabbit myocardium in vivo. *Circulation.* 1993 Oct;88(4 Pt 1):1931-1936.
32. Wada K, Ito M, Miyazawa T, Katoh H, Nawashiro H, Shima K, Chigasaki H. Repeated hyperbaric oxygen induces ischemic tolerance in gerbil hippocampus. *Brain Res.* 1996; 740:15-20.
33. Sharifi M, Fares W, Abdel-Karim I, Koch JM, Sopko J, Adler D; Hyperbaric Oxygen Therapy in Percutaneous Coronary Interventions Investigators. Usefulness of hyperbaric oxygen therapy to inhibit restenosis after percutaneous coronary intervention for acute myocardial infarction or unstable angina pectoris. *Am J Cardiol.* 2004 Jun 15;93(12):1533-1535.
34. Alex J, Laden G, Cale A, Bennett S, Flowers K, Madden L, Gardiner E, McCollum T, Griffin S. Pretreatment with hyperbaric oxygen and its effect on neuropsychometric dysfunction and systemic inflammatory response after cardiopulmonary bypass: A prospective randomised double-blind trial. *J Thorac Cardiovasc Surg.* 2005;130(6):1623-1630.
35. Yogaratnam JZ, Laden G, Guvendik L, Cowen M, Cale A, Griffin S. Hyperbaric oxygen preconditioning improves myocardial function, reduces length of intensive care stay, and limits complications post coronary artery bypass graft surgery. *Cardiovasc Revasc Med.* 2010;11:8-19.
36. Li Y, Dong H, Chen M, Liu J, Yang L, Chen S, Xiong L. Preconditioning with repeated hyperbaric oxygen induces myocardial and cerebral protection in patients undergoing coronary artery bypass graft surgery: a prospective, randomized, controlled clinical trial. *J Cardiothorac Vasc Anesth.* 2011 Dec;25(6):908-916.
37. Liu Y, Sun XJ, Liu J, Kang ZM, Deng XM. Heme-oxygenase-1 could mediate the protective effects of hyperbaric oxygen preconditioning against hepatic ischemia-reperfusion injury in rats. *Clin Exp Pharmacol Physiol.* 2011;38:675-682. ♦